ARCH Venture Partners Invests in Rapport Therapeutics $100M Series A
Gunderson Dettmer represented client ARCH Venture Partners as an investor in the $100 million Series A financing of Rapport Therapeutics, a clinical stage biotech. Rapport Therapeutics is transforming the treatment of neurological disorders through the discovery and development of precision medicine. The new capital will be used to accelerate growth, expand operations and its business reach.
In the announcement of the transaction, Chief Executive Officer at Rapport, Abraham Ceesay said, “Rapport is bringing together pioneers in neuroscience to create revolutionary treatment options for patients who have long endured the shortcomings of nonspecific therapeutics. The era of precision neuroscience is upon us, and patients’ needs have never been greater. At Rapport we believe that by leveraging the discovery of receptor-associated proteins by our founders, we are poised to develop precision medicines that will greatly improve the lives of patients living with neurologic disorders.”
The Gunderson Dettmer deal team was led by Kirt Shuldberg and included Riley Millender.
ARCH Venture Partner